Shaniqua J. Anum, Julie Kanter/ scholars.uab.edu
Aug 23, 2026, 14:10
Intravenous Arginine Fails to Reduce Acute Sickle Cell Pain – JAMA
JAMA shared a post on LinkedIn about a recent article by Shaniqua J. Anum and Julie Kanter, adding:
”Acute pain episodes in Sickle Cell Disease remain a leading cause of emergency department visits and hospitalization, yet treatment still relies largely on opioids, nonsteroidal anti-inflammatory drugs, and intravenous fluids.
The STArT trial of intravenous Arginine found no overall benefit vs placebo, and heterogeneity in acute pain mechanisms and trial end points may have limited detection of a vascular-targeted treatment effect.”
Title: Arginine Treatment and Sickle Cell Disease Pain — A Great STArT, but a Hard End Point
Authors: Shaniqua J. Anum, Julie Kanter
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 7, 2026, 16:44Amor Salah: 2026 NCS/SCCM Guidelines for Managing Antithrombotic-Associated ICH
-
Oct 7, 2026, 16:04NETs in Thrombosis: From Mechanism to Therapeutic Target
-
Oct 7, 2026, 15:28Amir Samimi: Prognostic Value of Platelet Count in Resected HNSCC
-
Oct 7, 2026, 15:21Eloïse Laouenan: Bridging Immunity and Thrombosis in MVTE
-
Oct 7, 2026, 15:10Uthra Sundaram: Honouring Donors During International Plasma Awareness Week
-
Oct 7, 2026, 15:04Daniel Victor Ortigoza: Should Frail Older Patients With AF Switch From VKA to DOACs?
-
Oct 7, 2026, 14:53Susan Noone: Donor Turned Recipient Shares Lifesaving Transfusion Story
-
Oct 7, 2026, 14:49Aimee Burtenshaw: The Impact of the Infected Blood Inquiry on Hospital Transfusion Laboratories
-
Oct 7, 2026, 14:41Vikash Jaiswal: Does Timing Matter for Calcium in Pre-Eclampsia Prevention?